Concord Biotech Limited
Lalit Sethi has extensive work experience spanning over several companies in various roles. Lalit most recently served as the Chief Financial Officer (CFO) at Concord Biotech Limited, where they were responsible for overseeing multiple functions and successfully launching the Initial Public Offer (IPO). Prior to that, Lalit served as the Group Financial Controller at AbhijeetGroup, focusing on improving productivity, cost rationalization, and capital designing and fundraising. Lalit also served as the Chief Operating Officer at Standard Pharmaceuticals Limited, where they significantly improved productivity and profitability through effective management practices. Lalit's experience also includes their role as President & CFO at Tilaknagar Industries Ltd., where they led multiple acquisitions, implemented ERP systems, and achieved significant market capitalization growth. Lalit has also held positions at HPL ADDITIVES LIMITED and Dabur India Limited, where they played key roles in project finance, ERP implementation, sales accounting, and tax management. Earlier in their career, they served as Chief Accountant at Oberoi Hotels & Resorts. Overall, Lalit's work experience demonstrates their expertise in financial management, strategic planning, and driving organizational growth.
Lalit Sethi pursued their education from 1985 to 1988 at The Institute of Chartered Accountants of India. During this time, they earned a degree in Chartered Accountancy. Unfortunately, no specific field of study was provided for this educational experience.
Concord Biotech Limited
Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing. The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.